Apogee Therapeutics, Inc. (NASDAQ:APGE) Sees Significant Decline in Short Interest

Apogee Therapeutics, Inc. (NASDAQ:APGE) was the recipient of a significant decline in short interest in September. As of September 30th, there was short interest totalling 7,230,000 shares, a decline of 11.7% from the September 15th total of 8,190,000 shares. Based on an average trading volume of 423,100 shares, the days-to-cover ratio is currently 17.1 days. Approximately 19.9% of the company’s stock are short sold.

Apogee Therapeutics Trading Down 2.0 %

Shares of APGE opened at $55.81 on Tuesday. Apogee Therapeutics has a 12 month low of $14.19 and a 12 month high of $72.29. The stock has a fifty day moving average price of $50.78 and a 200-day moving average price of $48.74. The firm has a market cap of $3.26 billion, a PE ratio of -10.63 and a beta of 2.75.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.60) EPS for the quarter, hitting analysts’ consensus estimates of ($0.60). As a group, research analysts forecast that Apogee Therapeutics will post -2.57 EPS for the current year.

Insider Activity at Apogee Therapeutics

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 40,000 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $40.62, for a total transaction of $1,624,800.00. Following the transaction, the chief executive officer now owns 1,434,487 shares of the company’s stock, valued at approximately $58,268,861.94. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $40.62, for a total value of $1,624,800.00. Following the transaction, the chief executive officer now owns 1,434,487 shares in the company, valued at $58,268,861.94. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jane Henderson sold 6,000 shares of the stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $48.26, for a total transaction of $289,560.00. Following the sale, the chief financial officer now directly owns 200,871 shares of the company’s stock, valued at approximately $9,694,034.46. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 146,665 shares of company stock worth $7,058,635 over the last three months. 36.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Apogee Therapeutics

A number of large investors have recently bought and sold shares of the company. Handelsbanken Fonder AB lifted its stake in Apogee Therapeutics by 25.7% during the 3rd quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company’s stock valued at $517,000 after acquiring an additional 1,800 shares during the period. SG Americas Securities LLC purchased a new stake in Apogee Therapeutics in the third quarter valued at $475,000. Perceptive Advisors LLC grew its position in Apogee Therapeutics by 2.2% during the 2nd quarter. Perceptive Advisors LLC now owns 2,105,636 shares of the company’s stock worth $82,857,000 after purchasing an additional 45,241 shares during the period. Driehaus Capital Management LLC raised its stake in shares of Apogee Therapeutics by 2.6% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,117,870 shares of the company’s stock valued at $83,338,000 after buying an additional 54,107 shares during the last quarter. Finally, Dark Forest Capital Management LP lifted its holdings in shares of Apogee Therapeutics by 78.3% in the 2nd quarter. Dark Forest Capital Management LP now owns 14,083 shares of the company’s stock valued at $554,000 after buying an additional 6,186 shares during the period. Hedge funds and other institutional investors own 79.04% of the company’s stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.